










DEEP EXPERIENCE. SHARED COMMITMENT.
"We take a private equity approach to a sector that’s traditionally been dominated by venture and early-stage growth firms. We'll work very closely with management to improve the operations of the business, update the product portfolio and revamp the commercial organization. We provide the support and resources our portfolio companies need to succeed.”
news
Aug 17, 2023
Keystone Dental Holdings and Check-Cap Ltd Enter into Definitive Business Combination Agreement
Proposed business combination to create a Nasdaq-listed medical device company focused on advancing the commercial execution and market development of Keystone’s comprehensive portfolio of implants, arches and other tooth replacement solutions. Keystone 2022 revenues exceeded $60 million. The combined company will trade on the NASDAQ with the ticker “KSD"Keystone 2022 revenues exceeded $60 million. The combined company will trade on the NASDAQ with the ticker “KSD"
Dec 28, 2022
Minerva Surgical Announces $30 Million Private Placement of Common Stock Led by Accelmed PartnersMinerva Surgical, Inc. a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has entered into a share purchase agreement for the sale of 146,627,565 shares (subject to adjustment for any stock split occurring prior to closing) of its common stock in a private placement, led by Accelmed, with participation by New Enterprise Associates, at an offering price of $0.2046 per share (subject to adjustment for any stock split occurring prior to closing). Following the offering, Accelmed will become the controlling stockholder of Minerva Surgical.
Dec 20, 2022
Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for SchizophreniaBoehringer Ingelheim and Click Therapeutics today announced the launch of an expanded collaboration for the development and commercialization of a second prescription-based digital therapeutic (PDT). The companies will collaborate to develop and commercialize a novel mobile application, which combines multiple clinically validated therapeutic interventions for use alone and in combination with pharmaceutical therapy to help people with schizophrenia achieve positive clinical outcomes.
Dec 16, 2022
Click Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic to Treat Episodic MigraineClick Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for CT-132. Click’s CT-132 prescription digital therapeutic is under development as an adjunctive preventive treatment for episodic migraine in patients aged 18 years and older.
Contact Us